Literature DB >> 22589409

Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer.

Marta Llauradó1, Blanca Majem, Josep Castellví, Sílvia Cabrera, Antonio Gil-Moreno, Jaume Reventós, Anna Ruiz.   

Abstract

Epithelial ovarian cancer is the most lethal gynecologic malignancy and the fifth leading cause of cancer death in women in the Western world. ETS transcription factors have been implicated in the regulation of gene expression during a variety of biologic processes including cell growth and differentiation. We recently examined the role of the ETS transcription factor ETV5 in epithelial ovarian cancer and described ETV5 as being upregulated in ovarian tumor samples as compared with ovarian tissue controls. In ovarian cancer cells, we showed that ETV5 regulated the expression of cell adhesion molecules, enhancing ovarian cancer cell survival in anchorage-independent conditions and suggesting that it plays a role in ovarian cancer cell dissemination and metastasis into the peritoneal cavity. To understand the role of ETV5 transcription factor during ovarian cancer cell dissemination, we analyzed by gene expression microarray technology those genes whose expression was altered in an ovarian cancer cell line with a stable downregulation of ETV5. The analysis of the genes and signaling pathways under the control of ETV5 in OV90 cells has unraveled new signaling pathways that interact with ETV5, among them the cell-cycle progression and the TGFβ signaling pathway. In addition, we found that the downregulation of ETV5 reduced the expression of the oncogenic transcription factor FOXM1. Consistently, FOXM1 was overexpressed in ovarian tumor samples, and its transcriptional levels increased with ETV5 transcription in ovarian tumor samples. Moreover, FOXM1 expression levels increased with tumor grade, suggesting a role in the progression of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589409     DOI: 10.1158/1541-7786.MCR-11-0449

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  11 in total

1.  Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion.

Authors:  Núria Pedrola; Laura Devis; Marta Llauradó; Irene Campoy; Elena Martinez-Garcia; Marta Garcia; Laura Muinelo-Romay; Lorena Alonso-Alconada; Miguel Abal; Francesc Alameda; Gemma Mancebo; Ramon Carreras; Josep Castellví; Sílvia Cabrera; Antonio Gil-Moreno; Xavier Matias-Guiu; Juan L Iovanna; Eva Colas; Jaume Reventós; Anna Ruiz
Journal:  Clin Exp Metastasis       Date:  2015-04-30       Impact factor: 5.150

2.  MicroRNA-194 inhibits the epithelial-mesenchymal transition in gastric cancer cells by targeting FoxM1.

Authors:  Zhenjun Li; Xiaojiang Ying; Hongliang Chen; Pingjiang Ye; Yi Shen; Weihuo Pan; Lihua Zhang
Journal:  Dig Dis Sci       Date:  2014-04-19       Impact factor: 3.199

3.  T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.

Authors:  Barbara Dziegielewska; Eli V Casarez; Wesley Z Yang; Lloyd S Gray; Jaroslaw Dziegielewski; Jill K Slack-Davis
Journal:  Mol Cancer Ther       Date:  2016-02-01       Impact factor: 6.261

4.  Evidence for independent evolution of functional progesterone withdrawal in primates and guinea pigs.

Authors:  Mauris C Nnamani; Silvia Plaza; Roberto Romero; Günter P Wagner
Journal:  Evol Med Public Health       Date:  2013-12-03

5.  Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.

Authors:  Xuan Zhang; Lihua Cheng; Kay Minn; Rashna Madan; Andrew K Godwin; Viji Shridhar; Jeremy Chien
Journal:  Oncotarget       Date:  2014-11-30

6.  ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.

Authors:  Erica di Martino; Olivia Alder; Carolyn D Hurst; Margaret A Knowles
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

Review 7.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

Review 8.  Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.

Authors:  W Ruprecht Wiedemeyer; Jessica A Beach; Beth Y Karlan
Journal:  Front Oncol       Date:  2014-03-03       Impact factor: 6.244

9.  Identification of potential functional genes in papillary thyroid cancer by co-expression network analysis.

Authors:  Zeng-Xin Ao; Yuan-Cheng Chen; Jun-Min Lu; Jie Shen; Lin-Ping Peng; Xu Lin; Cheng Peng; Chun-Ping Zeng; Xia-Fang Wang; Rou Zhou; Zhi Chen; Hong-Mei Xiao; Hong-Wen Deng
Journal:  Oncol Lett       Date:  2018-08-14       Impact factor: 2.967

10.  Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer.

Authors:  Haoran Feng; Kun Liu; Xiaonan Shen; Juyong Liang; Changgang Wang; Weihua Qiu; Xi Cheng; Ren Zhao
Journal:  Cell Death Dis       Date:  2020-10-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.